Home
overview

Visit the download centerto read our exclusive interviews with some of our featured speakers for 2018!

SMi Group is thrilled to announce the 20th Annual Superbugs & Superdrugs Conference in London on 19th – 20th March 2018. As the global threat of antimicrobial resistance continues to develop, it is clear that a global commitment is required in order to tackle the ever-increasing problem of multidrug-resistant bacteria.

This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.

 Join us to learn about various strategies in place to support antimicrobial resistance research & development, evaluate the latest scientific advancements for tackling antimicrobial resistance and consider potential novel candidates and alternatives to anti-microbials.

The event will also focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.

VIP Offer - To all the SMI delegates choosing to stay at the Copthorne Tara Hotel, we will offer an upgrade to a superior room and welcome drink voucher

 

Learn how GARDP are facilitating the research and development on new antibiotics


Hear from The Pew Charitable Trusts about their new digital platform SPARK, allowing researchers to share data, ideas, and insights to spur the discovery of innovative new antibiotics


Discover how Oppliotech is using a systems biology approach to develop antibacterial drugs: through a computational network model to guide the identi?cation of potentiator targets


Examine the latest novel candidates and alternatives to antibiotics including Contrafect’s Lysin Products and Professor Ian Henderson’s research using apheresis

Ensure compliance through regulatory updates on policy and planned revisions to EMA guidance
 

Previous attendees include:

7i Med Ltd; ACT Surfaces ; Alacrita LLP; Anti-infectives ; Antikor Biopharma; Arsanis Biosciences GmbH; Auspherix Ltd; BARDA; BIOASTER; Blueberry Therapeutics Ltd. ; Cantab Anti-infectives; Cempra Pharmaceuticals; Centauri Therapeutics; Chemical Biology Ventures; Clarivate Analytics; Da Volterra; Drugs for Neglected Diseases initiative (DNDi); dstl (Defence Science and Technology Laboratory); Elsevier; Emergent BioSolutions; Emergent BioSolutions Inc.; European Commision; Evotec; F. Hoffmann-La Roche; F. Hoffmann-La Roche Ltd.; Fidelta Ltd; GOETZPARTNERS CORPORATE FINANCE LIMITED; Karolinska Institute; KWS BioTest; Laboratoire Biodim; Medecins Sans Frontieres; MGB Biopharma; MHRA; Mutabilis S A; Neem Biotech; Nemesis bioscience ; NeoSome Life Sciences, LLC; Northern Antibiotics Ltd.; Nosopharm; Office of Health Economics (OHE); Phico Therapeutics; Phico Therapeutics Ltd; Polyphor Ltd; QuantumDX; Sankio Pharma Gmbh; Spero Therapeutics; St George's, University of London; The Wellcome Trust; Tiber Creek Partners; TNO Pharma; TranScrip Partners; TranScrip Partners LLP; University Hospital of Copenhagen ; University Of Liverpool; University of North Texas Health Science Center; Venaticus Symcel ; VIB; Wellcome Trust;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks: What has happened over the last year and prospects for the future?

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners
View Bio

9:15 GARDP: an alternative model to antibiotic drug development

Jean-Pierre Paccaud

Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
View Bio

  • GARDP is a not-for-profit R&D organisation developing new treatments to tackle drug-resistant bacterial infections, and aiming at delivering them in a responsible, sustainable and accessible manner.
  • Public-private partnerships contributions to fight AMR: collaboration and complementarity.
  • Experimenting alternative business models to deliver innovation.
  • Current programs and deals will be presented. 
  • 9:50 Incentivizing Antibacterial Research and Development

    Mark Albrecht

    Mark Albrecht, Health Scientist, HHS/ASPR/BARDA

    - What is BARDA and why is it interested in AMR
    - How BARDA partners with industry to stimulate innovation in AMR R&D
    - How CARB-X is refilling the preclinical AMR product pipeline

    10:25 Encouraging appropriate use of antibiotics: The role of industry in supporting the efforts of national policy-makers

    Steve Holden

    Steve Holden, Medicial Adviser, MSD
    View Bio

    •What is appropriate antibiotic usage and what role could industry have in this?
    •Is the “antibiotic apocalypse” a potential reality and why are we running out of antibiotics? 
    •The concept of de-linkage and industry’s contribution to making this work

    11:05 Morning Coffee

    11:35 Replenishing and enabling the pipeline for anti-infective resistance

    Emmanuelle Coutanceau

    Emmanuelle Coutanceau, Principal, Novo AS
    View Bio

    - Funding gap and funding options
    - Process and strategy

    12:05 Bacterial cybergenetics to resurrect sensitivity to antibiotics in anti-microbial resistant (AMR) pathogens

    Conrad Lichtenstein

    Conrad Lichtenstein, CSO, Nemesis bioscience
    View Bio

    • “Nemesis Symbiotics” use programmable RNA-guided DNA endonuclease gene editing technology to target antibiotic resistance genes.
    • A single Symbiotic inactivates members of multiple families of resistance genes –so resurrecting sensitivity to antibiotics.
    • Pre-clinical studies show that Transmids, our novel vectors, deliver Symbiotics to bacteria by phage-coat infection and subsequently spread by bacterial conjugation.
    • Symbiotics are biological companion therapeutics to be used together with well-established antibiotics for both therapeutic treatment of infection as well as prophylactic treatment preventing the spread of AMR.

    12:40 Using immune modulation alongside antibiotics to counter multidrug-resistant bacteria

    David Brown

    David Brown, Managing Director and Founder, Alchemy Biomedical Consulting
    View Bio

    • The antibiotic field can arguably learn from oncology where immune modulation used alongside chemotherapy has transformed treatment prospects.
    • Similarly, to beat resistant bacteria, we need to counter the way they usurp our immune defenses to evade antibiotics.
    • Summarising novel ideas on using immune modulation alongside antibiotics to beat resistant species.
    • Suggesting that adding a third component could reduce death rates from sepsis which remain very high even with use of modern antibiotics.

    13:15 Networking Lunch

    14:15 SPARKing New Antibiotic Discovery – the Shared Platform for Antibiotic Research and Knowledge

    Kathy Talkington

    Kathy Talkington, Project Director, Pew charitable trusts
    View Bio

    • The Shared Platform for Antibiotic Research and Knowledge is a groundbreaking and dynamic information-sharing platform.
    • Bringing together curated antibiotic discovery data and cutting-edge analytics to help scientists tackle the scientific barriers blocking antibiotic discovery.
    • While the global threat of antibiotic resistance continues to rise, nearly every antibiotic in use today is based on a discovery from more than 30 years ago.
    • SPARK will focus on the unique challenges of finding and designing antibiotics that can defeat drug-resistant Gram-negative bacteria, which are among the hardest-to-treat superbugs
     

    14:50 Use of the PasNas platform to enable high quality antibacterial hit finding

    Domingo  Gargallo-Viola

    Domingo Gargallo-Viola, Chief Scientific Officer, ABAC Therapeutics
    View Bio

    • The infectious diseases drug discovery is enormously inefficient. We can not repeat things over and over again. What can we do to change this trend?
    • Disruptive Innovation to control risk factors, improve efficiency and ensure delivery. 
    • New paradigms in infectious diseases, from magic bullet to precision antibacterial agents
     

    15:25 Building a detailed computational network model of cell envelope biogenesis: a systems biology approach to developing antibacterial drugs (potentiators)

    John George

    John George, CSO, Oppilotech
    View Bio

    • Model incorporates the synthesis of key components including LPS, phospholids and peptidoglycan
    • The model is used to guide the identification of potentiator targets– agents that can enhance the activities of existing antibiotics
    • Potentiator programmes derived from model
     

    16:00 Afternoon Tea

    16:30 Teaching old cephalosporin dogs new mechanistic tricks against MDR Gram-negative bacteria

    Larry Sutton

    Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
    View Bio

    • Cephalosporin synthetic scaffolding for new mechanisms
     In vitro activity versus WHO critical priority pathogens
    • Comparison to new combination β-lactams
    • In vivo performance

    17:05 Novel virulence factors of Acinetobacter baumannii as targets for antibacterial development

    Daniel  Zurawski

    Daniel Zurawski, Head, Antibacterial Discovery and Development, Walter Reed Army Institute Of Research
    View Bio

    • Over the past 3-4 years, my team has exploited a transposon mutant library to identify targets required for A. baumannii virulence in animal models of infection.
    • Some of these genes/proteins are novel targets on the surface of the bacterium that we are currently developing human monoclonal antibodies against.
    •  We have also identified some targets within the bacterium that could be drug-able.
    • As we learn and test more, we believe the true strength of our research is not a single attack against the bacteria, but rather a combination of multiple drugs/antibodies against different targets to render the bacteria avirulent and cleared by the immune system.
     

    17:40 Chairman’s Closing Remarks and Close of Day One

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures
    View Bio

    9:10 Funding, Filing, and Finance

    John  Rex

    John Rex, Chief Medical Officer , F2G Ltd

    • What’s up with funding initiatives: CARB-X update
    • Advances in regulatory tools: Tier C makes headway
    • Paying for it all: Evolving global discussions of payer models

    9:45 Regulatory considerations for the registration of new antibacterial agents

    Mair Powell

    Mair Powell, Senior clinical assessor, MHRA
    View Bio

    • Ensuring that candidate antibacterial agents with potential to address an unmet need are evaluated in line with regulatory guidance
    • Options for clinical development programmes
    • Importance of the pharmacokinetic-pharmacodynamic relationship 
    • Update on recent guidance and planned revisions to EMA guidance

    10:20 Tackling the current lack of incentives for people working in antimicrobial resistance research and development

    Adrian Towse

    Adrian Towse, Director, Office Of Health Economics
    View Bio

  • Analysis of the economic issues which affect the research and development of new antibiotics in the private sector?
  • How should payers and HTA bodies assess the value of a new antibiotic
  • What should the contractual balance be between market entry rewards and paying for value
  • How to ensure that ?nancial incentives for the private sector, do not prevent drug accessibility to developing countries?
     
  • 10:55 Morning Coffee

    11:25 Drug-resistant Infections Priority Programme – Transforming the way we work

    Ghada Zoubiane

    Ghada Zoubiane, Science Lead of the Drug-Resistant Infections Priority Programme, Wellcome
    View Bio

  • Learn Wellcomes strategy in Drug-Resistant Infections
  • Discover new ways Wellcome is working to make an impact
  • Discuss current activities and future plans to tackle AMR

     

  • 11:55 Iclaprim: a well differentiated, targeted, potent and rapidly bactericidal antibiotic against multidrug resistant bacteria

    David Huang

    David Huang, Chief Medical Officer, Motif BioSciences
    View Bio

    • Exploring a novel mechanism of action different from any other antibiotic currently in development
    • Positive clinical outcomes among patients with ABSSSI and HAP/VAP through optimizing iclaprim's dose and the concentration at sites of infection
    • Looking into safety data and what lies ahead to achieve FDA and EMA approval

    12:30 Unlocking Reactive Oxygen: A New Generation of Antimicrobials

    Matthew  Dryden

    Matthew Dryden, Chief Scientific Adviser, Matoke Holdings

    • Insight into the Reactive Oxygen mechanism
         o The microbiology
         o Potential formulations
    • Medical need
         o Tackling the World Health Organisation’s most deadly bacteria
    • Navigating the UK regulatory process
    • What’s next for Matoke and Reactive Oxygen

    13:05 Networking Lunch

    14:05 Challenges in Antimicrobial Evaluation of Novel Therapies using Animal Models

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
    View Bio

    • Where to start / What model to use
    • Dose / Regimen – How to choose
    • Test articles with no intrinsic activity
    • How to evaluate combination therapy
    • What does the data tell us?
     

    14:40 Lysins: Alternative Antimicrobials to Improve Clinical Outcomes Serious Bacterial Infections - CF-301 - A Case Study

    Cara Cassino

    Cara Cassino, Chief Medical Officer, ContraFect
    View Bio

    • CF-301 demonstrates the hallmark features of lysins, including: rapid, targeted bacteriolysis, potent synergy with conventional antibiotics, activity against antibiotic-resistant strains, low propensity for resistance and remarkable biofilm eradication, which make lysins attractive therapeutic candidates for serious bacterial infections.
    • In vivo studies with CF-301 signal the therapeutic potential of lysins boost the efficacy of conventional antibiotics and combat antimicrobial resistance 
    • The ongoing CF-301 clinical development program will help define the place in therapy for ability of lysin therapeutics in the treatment of serious, invasive, biofilm-dependent bacterial infections is being evaluated in clinical development
     

    15:15 Afternoon Tea

    15:45 C. auris – a difficult to treat, emerging pathogen

    Stephen Barat

    Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    View Bio

    • Brief history of C. auris
    • How C. auris differs from other candida species
    • Experimental models of C. auris
    • New potential treatments

    16:20 Amelioration of multi drug resistant infection by antibody modulation

    Ian Henderson

    Ian Henderson , Professor of Microbial Biology, University Of Birmingham
    View Bio

    • Some individuals overproduce antibody that recognises surface structures on bacteria
    • Such antibody interferes with serum killing of the bacterium
    • Removal of these antibodies by apharesis restores serum killing
    • Restoration  of serum killing is associated with clinical improvement

    16:55 Chairman’s Closing Remarks and Close of Day Two

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures
    View Bio

    +

    FEATURED SPEAKERS

    Adrian Towse

    Adrian Towse

    Director, Office Of Health Economics
    Emmanuelle Coutanceau

    Emmanuelle Coutanceau

    Principal, Novo AS
    Ghada Zoubiane

    Ghada Zoubiane

    Science Lead of the Drug-Resistant Infections Priority Programme, Wellcome
    John  Rex

    John Rex

    Chief Medical Officer , F2G Ltd
    Steve Holden

    Steve Holden

    Medicial Adviser, MSD

    Adrian Towse

    Director, Office Of Health Economics
    Adrian Towse

    Adrian Towse is the Director of the Office of Health Economics. The Office of Health Economics is a not-for-profit company, and a registered charity under UK law, conducting research and provides (through a subsidiary company) consultancy services on health economics and related policy issues that affect health care and the life sciences industries. It is owned by the Association of the British Pharmaceutical Industry (ABPI) but operates at arm’s length. It has a staff of 20 people. It works in three areas:
    • the economics of the financing and organisation of health care;
    • the economic evaluation of medicines including HTA;
    • the economics of life sciences innovation.

    Activities
    Adrian researches in all three of OHE’s core areas of activity. Current research includes the use of 'risk-sharing' arrangements between health care payers and pharmaceutical companies, including approaches to value-based assessment; the economics of stratified/personalised medicine for health care payers and the pharmaceutical industry; economic issues that affect both R&D for and access to treatments for diseases prevalent in middle and low income countries; and measuring productivity in health care.
    Adrian is currently a Visiting Professor at the London School of Economics and a Senior Visiting Fellow at the Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford. He has also has been a Visiting Professor at the Department of Economics and Related Studies, University of York. For ten years he served as a Non-Executive Director of the Oxford Radcliffe NHS Trust (now the Oxford University Hospitals NHS Trust), one of the UK’s largest research and teaching hospitals. He served at various times as chair of its Governance Committee, chair of its Audit Committee, and chair of its Relocation Board (overseeing the closure of the Radcliffe Infirmary site and the opening of the West Wing and the Cancer Centre).
    Adrian served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for the 2014-15 term and currently serves on the Board of Directors as Past-President.

    Cara Cassino

    Chief Medical Officer, ContraFect
    Cara Cassino

    Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including extensive experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and globally. Dr Cassino joined ContraFect Corporation in 2015 and currently serves as Executive Vice President of Research and Development, and Chief Medical Officer. Prior to joining ContraFect, Dr. Cassino served as Senior Vice President at Forest Laboratories, Inc (acquired by Actavis plc, now Allergan plc), where she oversaw Global Clinical Development across 4 therapeutic areas, including Antiinfectives. While at Forest, she was responsible for pre- and post-marketing clinical activities for a portfolio of 35 compounds, and also clinical due diligence for M&A activity including the $2.9 billion acquisition of Aptalis Pharma and the $1.1 billion acquisition of Furiex Pharmaceuticals. Prior to this, Dr. Cassino held a number of senior executive positions at Pfizer, including Global Medical Team Leader of Pfizer's antibacterial franchise which included Zyvox (linezolid) and Medical Development Group VP for Pulmonary Vascular Disease and Rare Diseases. Dr. Cassino also served as Executive Medical Director for the late stage US respiratory franchise at Boehringer-Ingelheim Pharmaceuticals, Inc, and was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at New York University School of Medicine.


    Dr. Cassino received her BA, summa cum laude, in Chemistry and Fine Arts from New York University (NYU) where she was elected Phi Beta Kappa, followed by an M.D. from NYU School of Medicine. Dr. Cassino completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital and a fellowship in Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Center. Dr Cassino is Board Certified in both internal medicine and pulmonary medicine.
     

    Conrad Lichtenstein

    CSO, Nemesis bioscience
    Conrad Lichtenstein

    In 2014, Professor Conrad Lichtenstein, CSO, co-founded Nemesis Bioscience to use RNA-guided endonucleases for AMR inactivation. Previously, as CSO for Population Genetics Technologies, he developed bar-coding for simultaneous analysis of candidate genes in multiple genomes and the identification of rare variants in mixed DNA samples.

    After a PhD at the MRC Laboratory of Molecular Biology in Cambridge, and a post-doctoral position at the University of Washington, Seattle, he held a faculty position at Imperial College London, and was then Professor of Molecular Biology at Queen Mary, University of London.

    His research has included gene targeting by homologous recombination, RNAi engineering and transposition by DNA elements spreading antibiotic resistance in bacteria.
     

    Daniel Zurawski

    Head, Antibacterial Discovery and Development, Walter Reed Army Institute Of Research
    Daniel  Zurawski

    From 2009 to present, Dr. Zurawski was contracted by the U.S. Army to manage a laboratory in the Wound Infections Department (WID) at Walter Reed Army Institute of Research (WRAIR). In 2017, he was made a civilian employee and promoted to Head of Antibacterial Discovery and Development. He is also an adjunct professor at the University of Maryland Dental School in the Department of Microbial Pathogenesis. His laboratory utilizes the disciplines of genetics, biochemistry, animal modeling, and cell biology in order to design and test novel antimicrobial and diagnostic strategies against MDR-ESKAPE pathogens that plague both the wounded soldiers as well as civilians. He and his group have developed useful genetic tools to better understand the pathogenesis of Acinetobacter baumannii in order to identify new targets that can be exploited for drug design. They also developed novel animal models in mice, rats, and swine that incorporate different infection sites, different drug deliveries, multiple endpoints, and bioluminescent bacteria to address the efficacy of any antimicrobial treatment. In addition to his team’s intramural research with the Army, Dr. Zurawski has ongoing extramural collaborations with industry, government, and academic partners to test their novel antibacterial strategies, where the animal models that were developed by his team provide crucial preclinical data on efficacy and toxicity. Dr. Zurawski has four patents on antibacterial therapies and has published over 38 papers on the bacterial pathogens.

    Dr. Zurawski received his B.A. from the University of Pennsylvania and his Ph.D. from the University of Vermont. Before graduate school, he worked as a technician in academia and in the pharmaceutical industry. After his thesis work on mechanisms of Salmonella pathogenesis, Dr. Zurawski did post-doctoral research at the Uniformed Services University of Health Sciences on novel effector proteins secreted by Shigella and was subsequently recruited by the WRAIR to initially work on developing Shigella vaccines.
     

    David Brown

    Managing Director and Founder, Alchemy Biomedical Consulting
    David Brown

    Dr Brown has 40 years experience in the pharmaceutical / biotechnology industry. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team developed Viagra through to proof of clinical efficacy in male impotence. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.
    He subsequently co-founded antibody company Crescendo Biologics and Healx Ltd which uses machine-learning to find life-saving therapies for children with rare diseases. His personal research is dedicated to solving the looming problem of antibiotic resistance.
     

    David Huang

    Chief Medical Officer, Motif BioSciences
    David Huang

    Dr. Huang is a senior pharmaceutical research executive, and the former Chief Medical Officer at ContraFect Corporation. Dr. Huang also led a drug development group in anti-infectives at Pfizer. Dr. Huang has over 15 years of clinical, academic and research experience in infectious diseases. He has served as a faculty member at Baylor College of Medicine and currently as an adjunct Assistant Professor at Rutgers New Jersey Medical School. He continues to see patients at the Veterans Affairs Medical Center in Houston. His research interests include bacteriology and virology, especially the epidemiology, pathogenesis, and treatment of multi-drug resistant organisms. He is experienced in designing, executing and closing out Phase I – III clinical trials for both antibacterials and antiviral agents. Dr. Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine. He is board-certified in both internal medicine and infectious diseases.

    Domingo Gargallo-Viola

    Chief Scientific Officer, ABAC Therapeutics
    Domingo  Gargallo-Viola

    Domingo Gargallo-Viola. PhD in Sciences from University of Barcelona. Management Development Program from: IE Business School and IESE Business School. Over 30 years of experience in the pharmaceutical industry. Currently CSO at ABAC Therapeutics. Previously, Infectious Diseases Manager and Drug Discovery Director at Ferrer Laboratories. Before joining Ferrer in 2008, during 18 years, Director of Drug Discovery Biology and Project Leader at GSK. Formerly, Research Associate at the Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Department of Defense, Bethesda, Maryland. President of the he Spanish Network for the Discovery of New Antibiotics (AD-SP), and Vice-President of the Spanish Network for the Development of Alternative Methods in Animal Experimentation (REMA). Author of over 70 original articles in international journals. Recipient of several distinctions including the Henri Warembourg Faculty of Medicine Medal, awarded by the University of Lille; Medicines for Malaria Venture Project of the Year Awards 2003, 2004 and 2015; and five GSK R&D Recognition Awards.

    Emmanuelle Coutanceau

    Principal, Novo AS
    Emmanuelle Coutanceau

    Emmanuelle joined Novo Holdings A/S in 2015 and is Partner at Novo Seeds. She serves on the Boards of directors of Antag Therapeutics, Corwave, Inthera Bioscience, and MinervaX.

    Emmanuelle has more than 10 years of experience in venture capital. Prior joining Novo Seeds, Emmanuelle was Partner at Auriga Partners, where she was in charge of investments for Auriga IV Bioseeds, a fund dedicated to projects in infectiology and microbiology. From 2007 until 2014, she was investor in life sciences at Omnes capital.

    Emmanuelle obtained her PhD in microbiology for her work conducted at Pasteur Institute (Paris, France).

    Ghada Zoubiane

    Science Lead of the Drug-Resistant Infections Priority Programme, Wellcome
    Ghada Zoubiane

    Dr Ghada Zoubiane is the Science Lead of the Drug-Resistant Infections priority programme at Wellcome. In her role, she is shaping and delivering Wellcome’s antimicrobial resistance (www.wellcome.ac.uk/dri) strategy, bridging the gap between science and policy and providing the evidence base to inform decision making.

    Previously, Ghada has been at the UK Medical Research Council for over nine years leading on different areas of research including antimicrobial resistance, infectious diseases and public health. Ghada’s expertise is in building partnerships across different stakeholders on a national and international level. She established the UK AMR Funders' Forum in 2013 (comprising more than 17 different funders) and played a central role in international engagement with India, China and South Africa in AMR. She represented the UK at the Management Board of the European Joint Programming Initiative for AMR and was elected as a Steering Committee member and a Deputy Chair.

    Prior to the MRC, Ghada had over eight-year experience in basic and translational research including early stage drug discovery and development within both the public and the private sectors.

    Ian Henderson

    Professor of Microbial Biology, University Of Birmingham
    Ian Henderson

    Ian Henderson is Professor of Microbial Biology and Director of the Institute of Microbiology and Infection within the College of Medical and Dental Sciences at the University of Birmingham. He studied Microbiology at University College Dublin. After graduation he worked as a research assistant at the Wellcome Laboratories. He returned to study for a PhD in molecular bacteriology at Trinity College Dublin. His PhD led to a productive postdoctoral position at the Centre for Vaccine Development, University of Maryland. After his postdoctoral studies, he joined Queens University Belfast as a lecturer before moving to the University of Birmingham. He established a group investigating bacterial cell envelope biogenesis and the interaction of bacterial surface components with the host. Ian has published over 100 articles in the fields of bacteriology, biochemistry and infection immunology. He has received major grants from the MRC, BBSRC, and EU. He is Director of the Wellcome Trust PhD programme in Antimicrobials and Antimicrobial Resistance.

    Jean-Pierre Paccaud

    Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
    Jean-Pierre Paccaud

    Dr Paccaud is responsible for DNDi’s business development activities, including opportunity identification, contract structure and negotiations, and alliance management. Prior to joining DNDi, he served as Head of Business Development for R&D products at OM Pharma.
    Dr Paccaud also notably founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals. Before taking on entrepreneurial challenges in industry, Dr Paccaud spent more than 15 years in academia, working in immunology, diabetes, and cell biology.
    Trained as a molecular and cellular biologist, Jean-Pierre Paccaud completed his post-doctoral studies at the University of California at Berkeley, and earned his PhD at the University of Geneva School of Medicine.
     

    John Rex

    Chief Medical Officer , F2G Ltd
    John  Rex

    John George

    CSO, Oppilotech
    John George

    I completed my PhD at the University of Hertfordshire, in which I investigated the mechanism of action of the fluoroquinolones. I then completed postdoctoral fellowships at New York Medical College before moving back to the UK to carry out host-pathogen studies at the Institute of Child Health, UCL. In addition to being the CSO for Oppilotech, I am an academic at Leeds Beckett University. My research areas involve; the regulatory mechanisms underpinning microbial metabolism, computational biology and the characterisation of antimicrobial molecules.

    Kathy Talkington

    Project Director, Pew charitable trusts
    Kathy Talkington

    Kathy Talkington directs Pew’s work on antibiotics, which seeks to address the growing threat of antibiotic resistance by spurring the innovation of new antibiotics and ensuring the appropriate use of antibiotics in both human health care settings and in food animals.
    Before joining Pew, Talkington managed the immunization and infectious disease programs at the Association of State and Territorial Health Offices, where she developed policies on hospital acquired infections, antimicrobial resistance, and issues related to immunization. Previously, she led strategic initiatives and programs on a wide range of health care issues for numerous nonprofit advocacy organizations and also state and federal policymakers.
    Talkington has a bachelor’s degree from the University of Virginia and a master’s degree in public affairs from the University of Texas at Austin.

     

    Larry Sutton

    Scientific Founder, Gladius Pharmaceuticals
    Larry Sutton

    Larry Sutton is a graduate of the University of Iowa Medical Scientist Training Program earning his Ph.D. in physical organic chemistry. He completed residency training in clinical pathology at the University of Iowa and Primary Care at Broadlawns Medical Center. While practicing emergency medicine he used personal finances to gather proof-of-concept data that cephalosporin antibiotics can double as mechanism-based inhibitors of β-lactamases. Armed with angel financing he founded Sopharmia, Inc. to advance the technology. He currently serves as Scientific Founder of venture-backed Gladius Pharmaceuticals leading an accelerated drug discovery and development program targeting MDR Gramnegative infections.

    Lloyd Czaplewski

    Director, Chemical Biology Ventures
    Lloyd Czaplewski

    Lloyd Czaplewski has >25-years of biopharmaceutical and NCE discovery and development experience from concept to clinical evaluation across multiple therapeutic areas – including anti-infective indications. He is currently the founder and CEO of Abgentis Ltd which focuses on semi-synthetic aminocoumarin antibiotics; CSO of Persica Pharmaceuticals Ltd which focuses on chronic back pain and a Director of Chemical Biology Ventures Ltd which provides consulting services to biotech, academia and investors.

    Mair Powell

    Senior clinical assessor, MHRA
    Mair Powell

    Dr. Powell underwent post-graduate training in clinical microbiology and infectious diseases. After 11 years in hospital medicine she worked for two global pharmaceutical companies in the US and then returned to the UK to work for the MHRA. She is a member of the EMA’s Infectious Disease Working Party and was its chair for 6 years. She has been closely involved in all guideline development for anti-infective agents for 20 years. She is currently the chair of the EMA’s Vaccine Working Party and a member of the Scientific Advice Working Party.

    Mark Albrecht

    Health Scientist, HHS/ASPR/BARDA
    Mark Albrecht

    Mark Pulse

    Assistant Director, UNTHSC, PreClinical Services
    Mark Pulse

    Matthew Dryden

    Chief Scientific Adviser, Matoke Holdings
    Matthew  Dryden

    Richard Bax

    Senior Partner, TranScrip Partners
    Richard Bax

    Richard is a Pharmaceutical Physician with over 32 years of industry experience, including working for Glaxo, Hoechst-Roussel, Lilly and ICI (now Astra Zeneca). He was VP at SmithKline Beecham from 1991-1999, working in London and Philadelphia, in charge of Global Anti-infective Clinical Development, resulting in over 15 successful NDAs /MAAs and launches including Famvir/penciclovir, Bactroban and Augmentin BD. Between 2000 and 2003, Richard was Chief Scientist to Biosyn, a microbicide company based in Philadelphia. He subsequently joined Chiron as VP and Clinical Director Europe. He was involved in the set-up of the EU part of the company and the successful MAA of Cubicin. He left 2.5 years later when Novartis absorbed Chiron. In May 2007 he joined Viropharma as VP Clinical Director Europe and was involved in the set up of the EU company and the EU transplant maribivir phase 3 studies. Richard has been a pharmaceutical consultant to such companies as Bayer (Germany), British Biotech (UK), LG Pharma (Korea), Pantheco (Denmark), Quorex (US), Elitra (US), and Merlion (Singapore) and was also a member of their respective antibiotic advisory boards. He was also a member of various working parties of the BSAC,ESCMID, European Union Grant Committee, EFPIA, IFPMA, Wellcome Trust, Surgical Infection Society (US) and the working party of the WHO on Bacterial Resistance as well as a consultant to the office of AIDS Research NIH US.

    Stephen Barat

    Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    Stephen Barat

    Dr. Stephen A. Barat is the head of pre-clinical research and early development for Scynexis, a biotechnology company focused on the development and commercialization of novel anti-infective treatments for life-threatening infections. He is a member of Scynexis senior management team and has 20+ years of experience in global drug development and registration from large multi-national pharmaceutical companies. Externally, Dr. Barat is a member of the PQRI working group for leachable and extractable for parenteral drug products and a member of the USP expert panel for biocompatibility testing.

     

    Steve Holden

    Medicial Adviser, MSD
    Steve Holden

    Dr Stephen Holden joined MSD as a Medical Advisor in 2017, bringing his NHS experience to a cross-functional team committed to ensuring appropriate use of and access to antibiotics. Dr Holden was formerly a Consultant Medical Microbiologist in Nottingham and Head of Service from 2015. There, he chaired the hospital antimicrobial guidelines committee, developed an antimicrobial stewardship programme and was an active member of several medicines management committees. He has experience working with key external bodies including NICE. Dr Holden has published articles in peer-reviewed journals and has been invited to speak and chair sessions at international conferences.

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William Weiss

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William Weiss

    Before leading the PreClinical Services group, Bill was Director of Drug Evaluation at Cumbre Pharmaceuticals Inc. where he was responsible for animal efficacy models, pharmacology and all pre-clinical microbiology research and development efforts focused on the discovery & development of new antimicrobial agents. Prior to this, he was a Group Leader in Infectious Disease Discovery Research at Wyeth Research (Pfizer), Lederle Laboratories and Schering-Plough (Merck), holding various positions of responsibility in antibacterial, antiviral and antifungal drug discovery research for over 37 years. His responsibilities included leading in vitro and in vivo evaluation of novel test articles from medicinal synthetic and natural products chemistry. He has worked on numerous antibacterial programs including the development of the marketed antibiotics; Suprax, Zosyn and Tygacil. His expertise encompasses the development of animal research models, evaluation of new and novel therapeutic agents as well as pharmacokinetic / pharmacodynamic analysis. He has authored / co-authored over 90 research presentations and journal articles.

    Sponsors and Exhibitors

    Official Media Partner

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    [press-release] - Novo Holdings launches an impact fund

    Download

    [Interview] - BARDA

    Download

    [Welcome Letter] - Chairs of the event

    Download

    [Interview] - Chemical Biology Ventures

    Download

    [Interview] - TranScrip Partners

    Download

    [Interview] - Oppilotech

    Download

    [Interview] - Alchemy Biomedical Consulting

    Download

    [Interview] - ABAC Therapeutics

    Download

    [Presentation] - Christopher Houchens, BARDA

    Download

    [ATTENDEE LIST] - Superbugs and Superdrugs events

    Download

    Sponsors and Exhibitors


    MSD

    Sponsors and Exhibitors
    http://www.msd.com/

    For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.


    Novo Holdings

    Sponsors and Exhibitors
    http://www.novoholdings.dk

    Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in well-established companies within life science.

    Media Partners


    Global Biodefense

    Official Media Partner
    http://www.globalbiodefense.com/

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.


    Microbiology Society

    Official Media Partner
    http://www.microbiologysociety.org

    The Microbiology Society is a membership charity for scientists interested in microbes, their effects and their practical uses. It is one of the largest microbiology societies in Europe with a worldwide membership based in universities, industry, hospitals, research institutes and schools. Our members have a unique depth and breadth of knowledge about the discipline. The Society’s role is to help unlock and harness the potential of that knowledge.

    Media Partners


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Biomedicines Journal

    Supporters
    http://www.mdpi.com/journal/biomedicines

    Biomedicines (ISSN 2227-9059) is an open access journal devoted to research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. The aim of Biomedicines is publishing high quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, developmentand ultimately to clinical use. It is published quarterly online by MDPI with rapid publication. Biomedicines is covered by ESCI (Web of Science) and PubMed.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Infectious Diseases Hub

    Supporters
    http://www.id-hub.com

    Infectious Diseases Hub is a free-to-access website open to all researchers, students and anyone else who might have an interest in the many aspects of microbiology and virology. We offer easy access to breaking news, interviews, opinion pieces, peer-reviewed articles and multimedia features, with a strong focus on the rising issue of antimicrobial resistance. Microbiology is such a diverse and exciting area, and with the emergence of new technologies giving us the ability to study complex communities and rapidly sequence whole genomes, there has been something of a ‘revolution’. Keeping on top of such technological advances and the latest emerging diseases is at the heart of Infectious Diseases Hub, and you can take a look at up-to-date essential research and information on the site now.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Conference-Service.com

    Supporters
    http://www.conference-service.com/

    COMS is a web application for managing delegate registration, payment, paper submission and paper review. Written in Perl and C, with a MySQL database at the back end, it is a comprehensive and powerful, yet easy to use solution for online conference management.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.